Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence

Fig. 2

Recommended treatment options according to oncogene driver status and PD-L1 expression in non-small-cell lung cancer. Next generation tyrosine kinase inhibitors for each driver oncogenic aberrations are approved one after another, and novel immune check point inhibitors combination with or without platinum-based chemotherapy are established as standard treatment options for non-small cell lung cancer without druggable alterations. Nivolumab plus ipilimumab is an option for patients with PD-L1 tumor proportion score < 1% in addition to those with PD-L1 tumor proportion score ≥ 1%. ††High PD-L1 expression is defined as ≥ 50% of tumor cells or ≥ 10% of tumor-infiltrating immune cells by SP142 assay. CBDCA: Carboplatin; CDDP: Cisplatin; PTX: Paclitaxel; DTX: Docetaxel; PEM: Pemetrexed; nab-PTX: nanoparticle albumin bound Paclitaxel; BEV: bevacizumab; RAM: Ramucirumab; NIVO: Nivolumab; IPI: ipilimumab; Atezo: atezolizumab; Pembro: pembrolizumab

Back to article page